Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$118.79 USD
-2.00 (-1.66%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $118.32 -0.47 (-0.40%) 5:18 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.79 USD
-2.00 (-1.66%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $118.32 -0.47 (-0.40%) 5:18 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
Zacks News
FDA Approval Widens Medtronic's (MDT) TAVR Platform Reach
by Zacks Equity Research
Medtronic plc (MDT), a well established player in the medical technology, services and solutions space, recently announced FDA approval for the extended use of its self-expanding CoreValve Evolut transcatheter aortic valve replacement (TAVR) platform.
Myriad Genetics to Grow with Study Successes, New Alliances
by Zacks Equity Research
On Jul 6, we issued an updated research report on Myriad Genetics, Inc. (MYGN).
Investors Look for Gains as Abbott Labs Set to Acquire Alere
by Zacks Equity Research
On majority of Alere shareholders' recent approval in favor of the merger with Abbott (ABT), the deal is now expected to close by the end of third-quarter 2017.
Becton, Dickinson (BDX) Poised on C.R. Bard Acquisition
by Zacks Equity Research
On Jul 7, we issued an updated research report on Franklin Lakes, NJ-based Becton, Dickinson and Company (BDX).
ResMed Sees Potential in SDB Market, Eyes Global Growth
by Zacks Equity Research
On Jul 6, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).
Baxter and TAU Ink New Licensing Agreements through Ramot
by Zacks Equity Research
Baxter International (BAX) has recently teamed up with Tel Aviv University, Israel's largest research and teaching university (TAU), on two new licensing agreements through Ramot.
Mazor Expects Higher Q2 Revenues, Wins Mazor X Orders
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it expects to report second-quarter 2017 revenue of approximately $15.4 million compared with $8.3 million from the year-ago quarter.
Edwards Lifesciences' INSPIRIS RESILIA Valve Wins FDA Nod
by Zacks Equity Research
Edwards Lifesciences Corporation (EW) recently announced the receipt of FDA approval for its INSPIRIS RESILIA aortic valve.
Will Walgreens Gain from Revised Rite Aid Agreement?
by Zacks Equity Research
The new agreement would enable Walgreens Boots Alliance (WBA) to buy nearly half of the Rite Aid business at a deal value, almost one-third of the original price.
Envision Healthcare Rallies on Infinity Healthcare Buyout
by Zacks Equity Research
Envision Healthcare Corporation (EVHC) recently announced that Envision Physician Services has acquired Infinity Healthcare, a multi-specialty physician group practice.
Exactech (EXAC) Launches Application for Knee Replacement
by Zacks Equity Research
Gainesville, FL-based Exactech Inc. (EXAC) recently announced the launch of a new software application christened ExactechGPS TKA PLUS.
Civitas Solutions (CIVI) Acquires Country Life Care Center
by Zacks Equity Research
Civitas Solutions, Inc. (CIVI) recently announced the acquisition of Country Life Care Center, a rehabilitation and post-acute care facility located in Riverton, UT.
Patterson Companies Grapples with Multiple Issues: Dump Now?
by Zacks Equity Research
On Jul 4, we issued an updated research report on St. Paul, MN-based The Patterson Companies (PDCO).
Omnicell (OMCL) Rides on Acquisitions Amid Tough Competition
by Zacks Equity Research
On Jul 4, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Abbott Freestyle Libre System Gets Health Canada License
by Zacks Equity Research
Abbott Laboratories (ABT) recently announced the receipt of Health Canada license for its FreeStyle Libre Flash Glucose Monitoring System.
Veeva (VEEV) Set to Grow on Subscription Revenue Focus
by Zacks Equity Research
On Jul 4, we issued an updated research report on Pleasanton, CA-based Veeva Systems Inc. (VEEV).
PerkinElmer (PKI) Hits a 52-Week High on Multiple Positives
by Zacks Equity Research
PerkinElmer Inc. (PKI) rallied to a new 52-week high of $69.19 on Jul 3, closing lower at $67.73.
Here's Why You Should Dump Quality Systems (QSII) Stock Now
by Zacks Equity Research
On Jul 4, we issued an updated research report on Irvine, CA-based Quality Systems Inc (QSII) -- a developer and marketer of healthcare information systems.
Varian Halcyon System Gets 510(k) Approval from the FDA
by Zacks Equity Research
Palo Alto, CA-based manufacturer of medical devices and software, Varian Medical Systems, Inc. (VAR) recently announced the 510(k) approval for its Halcyon system.
Can The Uptrend Continue for Mesa Laboratories (MLAB)?
by Zacks Equity Research
Investors certainly have to be happy with Mesa Laboratories, Inc. (MLAB) and its short term performance
Obamacare Holds Ground: 3 Medical Device Stocks to Gain
by Zacks Equity Research
Republican leaders have failed to play their "Trump card" this time, courtesy of the pullback of the Republican healthcare bill, the American Health Care Act (ACHA), which was designed to repeal the Affordable Care Act (ACA) or Obamacare.
Five Recent Strong Buys In Two Industries
by Brian Bolan
Over the last week two industries saw at least five stocks became Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for June 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday